By Bryan Koenig ( August 16, 2021, 10:34 PM EDT) -- A biotechnology company fighting to avoid selling a psoriasis drug that's in development to Celgene, citing Bristol-Myers Squibb's $74 billion acquisition of the drugmaker and BMS' own competing treatment, invoked the Federal Trade Commission's outvoted Democrats in a New York federal court complaint on Friday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.